First Tracks Biotherapeutics (HAM:B43) Change In Inventory: €0.00 Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €37.60
! 2 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Change In Inventory?

First Tracks Biotherapeutics HAM:B43 -2.84% 20 Change In Inventory is €0.00 Mil as of Dec. 2024. GuruFocus rates HAM:B43 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

First Tracks Biotherapeutics's change in inventory for the quarter that ended in Dec. 2024 was €0.00 Mil. It means First Tracks Biotherapeutics's inventory stayed the same from Dec. 2023 to Dec. 2024 .

First Tracks Biotherapeutics's change in inventory for the fiscal year that ended in Dec. 2024 was €0.00 Mil. It means First Tracks Biotherapeutics's inventory stayed the same from Dec. 2023 to Dec. 2024 .

First Tracks Biotherapeutics's Total Inventories for the quarter that ended in Dec. 2024 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

First Tracks Biotherapeutics  (HAM:B43) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

First Tracks Biotherapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/0*365 / 2
=N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

First Tracks Biotherapeutics's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0 / 0
=N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

First Tracks Biotherapeutics's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Change In Inventory Related Terms

First Tracks Biotherapeutics Change In Inventory Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Change In Inventory Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Change In Inventory
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Change In Inventory 0.00 0.00
HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of €0.00 Mil mean?
First Tracks Biotherapeutics (HAM:B43) has a Change In Inventory of €0.00 Mil as of Dec. 2024. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Change In Inventory too high?
First Tracks Biotherapeutics' current Change In Inventory is €0.00 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Change In Inventory compare to AVLN and IMTX?
First Tracks Biotherapeutics' Change In Inventory of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Change In Inventory is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current Change In Inventory of €0.00 Mil. The current Change In Inventory is €0.00 Mil. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current Change In Inventory is €0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.60
Price